Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest LaboratoriesNSE:QUESTLAB -1.96%44 EV-to-FCF is -9.44 as of Jul. 22, 2026. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 44/100. The stock has 5 warning signs investors should review. Among 566 Drug Manufacturers companies, Quest Laboratories ranks worse than 176678.27% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Quest Laboratories's Enterprise Value is ₹1,507 Mil.
Quest Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-160 Mil. Therefore, Quest Laboratories's EV-to-FCF for today is -9.44.
The historical rank and industry rank for Quest Laboratories's EV-to-FCF or its related term are showing as below:
NSE:QUESTLAB'
s EV-to-FCF Range Over the Past 10 Years
Min: -15.24 Med: -4.71 Max: 124.51
Current: -9.37
During the past 6 years, the highest EV-to-FCF of Quest Laboratories was 124.51. The lowest was -15.24. And the median was -4.71.
NSE:QUESTLAB's EV-to-FCF is ranked worse than 100% of 566
companies
in the Drug Manufacturers industry
Industry Median: 20.945
vs NSE:QUESTLAB: -9.37
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Quest Laboratories's PE Ratio (TTM) for today is calculated as:
Quest Laboratories's share price for today is ₹95.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Quest Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹9.160.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Quest Laboratories EV-to-FCF Related Terms
Quest Laboratories EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Quest Laboratories's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:QUESTLAB vs LLY, JNJ, ABBV: EV-to-FCF Comparison
For the Drug Manufacturers - General subindustry, Quest Laboratories's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Laboratories EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Quest Laboratories's EV-to-FCF falls into.
Quest Laboratories's current Enterprise Value is ₹1,507 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Quest Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-160 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Laboratories (NSE:QUESTLAB) has a EV-to-FCF of -9.44 as of Jul. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Quest Laboratories and its competitors. According to the industry distribution chart, Quest Laboratories ranks #999999 out of 566 companies in the Drug Manufacturers industry.
Is Quest Laboratories' EV-to-FCF too high?
Quest Laboratories' current EV-to-FCF is -9.44. Based on the distribution chart, Quest Laboratories ranks #999999 out of 566 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Quest Laboratories has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Quest Laboratories ranks #999999 out of 566 companies for EV-to-FCF. This places Quest Laboratories in the lower half of its industry. The industry median EV-to-FCF is 20.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.95, based on 566 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Quest Laboratories and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Laboratories's current EV-to-FCF is -9.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current EV-to-FCF of -9.44. The current EV-to-FCF is -9.44. Quest Laboratories' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current EV-to-FCF is -9.44 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
44GF Score
Get the complete analysis for NSE:QUESTLAB
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QUESTLAB has been successfully added to your 
